# EDGAR Filing Document

**Accession Number:** 0001029142
**File Stem:** 9999999997-23-000290
**Filing Date:** 2023-1
**Character Count:** 2143
**Document Hash:** 911e3ab96f326e2fc619c7abc0f914af
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**9999999997-23-000290.hdr.sgml**: 20230124

**ACCESSION NUMBER**: 9999999997-23-000290

**CONFORMED SUBMISSION TYPE**: CT ORDER

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230124

**DATE AS OF CHANGE**: 20230124

**ACTION DATE**: 20230124

**RECEIVED DATE**: 20230124

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DYNAVAX TECHNOLOGIES CORP
- **CENTRAL INDEX KEY:** 0001029142
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 330728374
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CT ORDER
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34207
- **FILM NUMBER:** 23545861

**BUSINESS ADDRESS:**
- **STREET 1:** 2100 POWELL STREET
- **STREET 2:** SUITE 720
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
- **BUSINESS PHONE:** 5108485100

**MAIL ADDRESS:**
- **STREET 1:** 2100 POWELL STREET
- **STREET 2:** SUITE 720
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608

### Attached PDF Documents

**Attachment 1:** `filename1`

# **UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
January 24, 2023**

# **ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

# **Dynavax Technologies Corporation**

**File No. 1-34207 - CF#36042**

Dynavax Technologies Corporation submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 8, 2018.

Based on representations by Dynavax Technologies Corporation that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.33 through March 7, 2028

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Chief, Knowledge Management Office